Biomedical Pioneering Innovation Center

Contact

E-mail:yunlongcao@pku.edu.cn
Add:Rm. 102, Biomedical Pioneering Innovation Center, Integrated Science Research Center No.2,Peking University

Lab Web：http://yunlongcaolab.com/

Yunlong Cao

Resume

2024.03-Present, Principal Investigator, Peking-Tsinghua Center for Life Science

2023.03-Present BIOPIC, Assistant Professor Principle Investigator

2022.03-2023.03 BIOPIC,Co-PI

2019.09-2022.03 Biomedical Pioneering Innovation Center,Peking University（BIOPIC）Research Associate

2014-2019 Harvard University Department of Chemistry and Chemical Biology Ph.D., Chemistry Advisor: Xiaoliang Sunney Xie

2010-2014 Zhejiang University Chu Kochen Honors College B.S.,Physics

Research Interests

B cells play a central role in adaptive immunity which protects the body against foreign pathogens. Understanding adaptive humoral immune response lays the foundation for the development of broad-spectrum antibody drugs and vaccines. Our research is centered around B-cell adaptive immune response and antigen-antibody interaction, with focuses on the following fronts.

Predicting immune escape mutations of SARS-CoV-2 based on high-throughput antibody characterization;
Developing broad-spectrum nasal vaccines and antibody drugs against respiratory viral infections such as COVID-19 and influenza;
Probing the molecular mechanisms behind humoral immune imprinting, immune waning and long-term immune memory;
AI-driven de novo design of antibodies based on large-scale antigen-antibody interaction database.

Awards and Honors

2023.05 WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC 2023)

2023 Beijing Outstanding Yound Talent Award (ZhongGuanCun Award)
2023 The Coalition for Epidemic Preparedness Innovations (CEPI) Scientific Advisory Committee

2023.02 China's top 10 scientific advances in 2022

2023.01 China's top 10 advances in life sciences in 2022

2022.12 Nature’s “Ten people who helped shape science in 2022” (Nature’s 10)

2022.01 MIT Technology Review Innovators Under 35 China (TR35 China)

Selected Publication

Y. Cao*#, F. Jian#, J. Wang#, Y. Yu#, W. Song#, A. Yisimayi, J. Wang, R. An, X.Chen, N. Zhang, Y. Wang, P. Wang,L. Zhao, H. Sun, L. Yu, S. Yang, X. Niu, T. Xiao, Q. Gu, F. Shao, X. Xiao, Y. Xu, R. Jin, Z. Shen, Y. Wang* & X.S. Xie*, Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. (2022).
Y. Cao*#, A. Yisimayi#, F. Jian#, W. Song#, T. Xiao#, L. Wang#, S. Du#, J. Wang#, Q. Li#, X. Chen#, Y. Yu#, P. Wang,Z. Zhang, P. Liu, R. An, X. Hao, Y. Wang, J. Wang, R. Feng, H. Sun, L. Zhao, W. Zhang, D. Zhao, J. Zheng, L. Y,C. Li, N. Zhang, R. Wang, X. Niu, S. Yang, X. Song, Y. Chai, Y. Hu, Y. Shi, L. Zheng, Z. Li, Q. Gu, F. Shao, W.Huang, R. Jin, Z. Shen*, Y. Wang*, X. Wang*, J. Xiao* & X. S. Xie*, BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 608: 593-602. (2022).
Y. Cao*#, J. Wang#, F. Jian#, T. Xiao#, W. Song#, A. Yisimayi#, W. Huang#, Q. Li, P. Wang, R. An, J. Wang, Y. Wang, X. Niu, S. Yang, H. Liang, H. Sun, T. Li, Y. Yu, Q. Cui, S. Liu, X. Yang, S. Du, Z. Zhang, X. Hao, F. Shao,R. Jin, X. Wang*, J. Xiao*, Y. Wang* & X. S. Xie*, Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 602: 657-663. (2022).
Z. Cui#, P. Liu#, N. Wang#, L. Wang#, K. Fan#, Q. Zhu#, K. Wang#, R. Chen, R. Feng, Z. Jia, M. Yang, G. Xu, B. Zhu, W. Fu, T. Chu, L. Feng, Y. Wang, X. Pei, P. Yang, X. S. Xie, L. Cao*, Y. Cao*, X. Wang*, Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell. 185(5): 860-871. (2022).
S. Du#, Y. Cao#, Q. Zhu#, P. Yu#, F. Qi#, G. Wang, X. Du, L. Bao, W. Deng, H. Zhu, J. Liu, J. Nie, Y. Zheng, H. Liang, R. Liu, S. Gong, H. Xu, A. Yisimayi, Q. Lv, B. Wang, R. He, Y. Han, W. Zhao, Y. Bai, Y. Qu, X. Gao, C. Ji,Q. Wang, N. Gao, W. Huang, Y. Wang, X. S. Xie*, X. Su*, J. Xiao*, C. Qin*, Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.Cell. 183: 1013-1023.e13 (2020).
Y. Cao#, B. Su#, X. Guo#, W. Sun#, Y. Deng#, L. Bao#, Q. Zhu, X. Zhang, Y. Zheng, C. Geng, X. Chai, R. He, X. Li,Q. Lv, H. Zhu, W. Deng, Y. Xu, Y. Wang, L. Qiao, Y. Tan, L. Song, G. Wang, X. Du, N. Gao, J. Liu, J. Xiao, X. Su,Z. Du, Y. Feng, C. Qin*, C. Qin*, R. Jin*, X. S. Xie*, Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. Cell. 182: 73-84.e16 (2020).
C. Yue, W. Song, L. Wang, F. Jian, X. Chen, F. Gao, Z. Shen, Y. Wang, X. Wang*, Y. Cao*, ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. The Lancet Infectious Diseases (2022). https://doi.org/10.1016/S1473-3099(23)00010-5
Y. Cao*#, F. Jian#, Z. Zhang#, A. Yisimayi#, X. Hao#, L. Bao#, F. Yuan, Y. Yu, S. Du. J. Wang, T. Xiao, W. Song, Y. Zhang, P. Liu, R. An, P. Wang, Y. Wang, S. Yang, X. Niu, Y. Zhang, Q. Gu, F. Shao, Y. Hu, W. Yin, A. Zheng, Y. Wang, C. Qin*, R. Jin*, X. Xiao* & X. S. Xie*, Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Reports. 41(12): 111845 (2022).
Y. Cao*#, W. Song#, L. Wang#, P. Liu#, C. Yue#, F. Jian#, Y. Yu, A. Yisimayi, P. Wang, Y. Wang, Q. Zhu, J. Deng, W. Fu, L. Yu, N. Zhang, J. Wang, T. Xiao, R. An, J. Wang, L. Liu, S. Yang, X. Niu, Q. Gu, F. Shao, X. Xiao, B. Meng,R. K. Gupta, R. Jin, Y. Wang, X. S. Xie* & X. Wang*, Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host & Microbe. 30(11): 1527-1539. (2022).
F. Jian#, Y. Yu#, W. Song, A. Yisimayi, L. Yu, Y. Gao, N. Zhang, Y. Wang, F. Shao, X. Xiao, Y. Xu, R. Jin, Y. Wang,X. S. Xie* & Y. Cao*, Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.The Lancet Infectious Diseases. 22(11): 1535-1537. (2022).
H. Zheng#, Y. Cao*#, X. Chen#, F. Wang, Y. Hu, W. Song, Y. Chai, Q. Gu, Y. Shi, Y. Feng, S. Liu, Y. Xie, X. S. Xie,W. Jiang, Z. Shen*, Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study. Cell Research. 32: 781-784. (2022).
Y. Cao*#, X. Hao#, X. Wang#, Q. Wu#, R. Song, D. Zhao, W. Song, Y. Wang, A. Yisimayi, W. Wang, W. Zhang, J. Du, H. Yu*, X. S. Xie*, R. Jin*, Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell Research. 32: 107-109. (2022).
S. Du#, P. Liu#, Z. Zhang#, T. Xiao, A. Yasimayi, W. Huang, Y. Wang, Y. Cao*, X. S. Xie*, J. Xiao*, Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants. Cell Research. 31: 1130-1133. (2021).
Y. Cao*#, A. Yisimayi#, Y. Bai#, W. Huang#, X. Li#, S. Du#, T. Yuan#, R. An, J. Wang, T. Xiao, W. Ma, L. Song, Y. Li, X. Li, W. Song, J. Wu, S. Liu, X. Li, Y. Zhang, B. Su, X. Guo, Z. Zhang, Y. Wei, C. Gao, Y. Dou, X. Xu, N. Zhang, Y. Zhang, R. Shi, R. Jin, Y. Ma, B. Lu, Y. Feng*, C. Qin*, Y. Wang*, J. Xiao*, X. S. Xie*, Humoral immune response to circulating SARS-CoV-2 variants by inactivated and RBD-subunit vaccines. Cell Research. 31: 732–741. (2021).